Healthcare, Life Sciences and Pharmaceuticals · Published Nov 2023
Parkinson’s Disease Treatment Market
Parkinson’s Disease Treatment Market is expected to grow at 7.8% CAGR from 2023 to 2035. It is expected to reach above USD 9.54 Billion by 2035.
Market size
Growth trajectory through 2035
Parkinson’s Disease Treatment Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $4.83 Bn
- CAGR
- 6.70%
- Expansion
- 1.9×
Market shape
leading region
- Leading region
- Asia Pacific
- Top-5 concentration
- Medium · ~52%
Forces at play
▲ tailwind
- ▼ headwind
- Cost & supply-chain pressure
- Named players
- 5 profiled
- Growth peak
- 2027–2031
Latest development
Capacity announcements, M&A activity, product launches, and funding rounds tracked quarterly in the full report data pack.
- Study window
- 2021–2035
- Base year
- 2025 (actuals)
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Parkinson’s Disease Treatment Market today ($4.83 Bn base), and how fast will it grow at 6.7% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Who are the named competitors, and what's their tier / market position / product breadth?
- What are the top growth drivers and top restraints , with quantified CAGR impact?
- What regulatory shifts and recent tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising end-user demand and adoption cycles contribute an estimated +3.0% to CAGR through 2035, with sustained traction across major geographies.
- Government policy and regulatory tailwinds contribute an estimated +1.9% to CAGR, concentrated in APAC and EU markets through 2029.
- Technology maturation and cost decline contribute an estimated +1.5% to CAGR, accelerating across North America, Europe, and APAC.
Restraints
Holding it back
- Input cost volatility and supply chain risk moderate near-term CAGR by an estimated 1.2%, with global exposure across the forecast horizon.
- Competitive substitute technologies moderate CAGR by an estimated 0.8% from 2027 onwards, primarily in North America and Europe.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising end-user demand and adoption cycles | +3.0% | Global | Sustained |
| Government policy and regulatory tailwinds | +1.9% | APAC, EU | 2025–2029 |
| Technology maturation and cost decline | +1.5% | NA, EU, APAC | Accelerating |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Input cost volatility and supply chain risk | −1.2% | Global | Near-term |
| Competitive substitute technologies | −0.8% | NA, EU | 2027+ |
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $4.83 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
Asia Pacific leads regional demand at ~43.5% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Medium concentration. 0 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
Concentration snapshot
Top 5 players control ~45–60% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
1company
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
2companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
2companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Industry leader 1
Rank 01Share est. ~20%Revenue $■■■MHQ ■■■ -
Industry leader 2
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Industry leader 3
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Industry leader 4
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Industry leader 5
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
European Union
EU sector-specific directives and CE conformity assessment apply. Compliance workload tracks Green Deal and Digital Decade programme timelines. Full jurisdiction-specific detail in the report.
-
United States
Federal agency oversight combined with state-level programmes and incentive frameworks shape the domestic buy-side calculus. Full applicable rule set covered in the report.
-
China / APAC
National-level policy tenders and GB / JIS / IS / K standards set the pace for downstream OEM adoption across the APAC bloc. Report captures ministry-issued guidelines and provincial procurement scale-ups.
-
Global standards
ISO, IEC, and sector-specific international framework updates affect testing, certification, and inter-operability requirements. Full standards mapping in the report's compliance section.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of parkinson’s disease treatment market?
The parkinson’s disease treatment market is expected to grow at 7.8% CAGR from 2023 to 2030. It is expected to reach above USD 9.54 Billion by 2030 from USD 5.64 Billion in 2023. -
• What are some of the market's driving forces?
The major factors driving the parkison’s disease treatment market growth are the presence of strong product pipeline, approval of disease-modifying therapies, and rising disease burden of parkinson’s in developed countries. -
• Which are the top companies to hold the market share in parkinson’s disease treatment market?
Cerevel Therapeutics, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., AbbVie, Inc., GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, H. Lundbeck A/S, Supernus Pharmaceuticals, Inc, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Cipla Inc., Acadia are the major parkinson’s disease treatment market players. -
• Which is the largest regional market for parkinson’s disease treatment market?
The region's largest share is in North America. Products that is manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal.
The Parkinson’s Disease Treatment Market is projected to reach $9.24 Bn by 2035, up from $4.83 Bn in 2025 — a 6.70% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.